To investigate the effect of Kawasaki syndrome on myocardial function, as well as the influence of high-dose intravenous y-globulin therapy on resolution of functional abnormalities, we studied 98 patients with Kawasaki syndrome during five time intervals from onset of illness: 1) 10 days or less, 2) 11-31 days, 3) 1-3 months, 4) 3-12 months, and 5) 1-3 years. Normal controls included 48 children under age 8 years, without known cardiovascular disease. Using two-dimensional directed M-mode echocardiograms, we obtained chamber dimensions, fractional shortening, rate-corrected velocity of shortening (Vcfc) adjusted for end-systolic wall stress, and early diastolic function parameters that included adjusted peak rates of left ventricular dimension change, wall thinning, and their respective timing. Left ventricular systolic and diastolic dimensions were larger (both p<0.O1) in patients than in normal subjects in period 1. Stress-adjusted Vcfc was much lower in patients in the 3 months after disease onset; by period 5, contractility was comparable in patients and normal subjects. Adjusted indexes of early diastolic function did not differ significantly between patients and normal subjects. To investigate the effect of y-globulin, we analyzed data on 47 patients prospectively randomized to therapy with aspirin alone (n = 19, 40%) or to aspirin plus y-globulin, 400 mg/kg/day for 4 consecutive days (n=28, 60%). In period 1, before treatment, the two groups had mean fractional shortening and stress-adjusted Vcfc comparable to each other but much lower than those of normal subjects (pcO.OO1). Patients treated with aspirin alone continued to have diminished fractional shortening and Vcfc compared with normal subjects in periods 2, 3, and 4 (all pc0.05). In contrast, fractional shortening and Vcfc in y-globulin-treated patients in these periods were comparable to those of normal subjects. By period 5, no difference was detected in systolic function or contractility between either treatment group and normal subjects. We conclude that early abnormalities of left ventricular contractility and myocardial function, as assessed by echocardiography, generally resolve by 1-3 years after disease onset and that recovery is accelerated by administration of IVGG in the acute phase. (Circulation 1989; 79:1237 -1246 K awasaki syndrome is a febrile illness of unknown etiology that occurs primarily in infants and young children. First described in Japan in 1967, Kawasaki syndrome is now recognized worldwide in children of all racial groups. [1] [2] [3] [4] Coronary artery aneurysms or ectasia develop in approximately 15-25% of children with the disease and may lead to myocardial infarction, sudden death, or angina pectoris.5-8 Recently, therapy with intravenous y-globulin in the acute phase of Kawasaki syndrome has been shown to decrease the frequency of occurrence of coronary artery abnormalities. [9] [10] [11] [12] [13] Although depressed left ventricular function is a well-known feature of acute Kawasaki 
Data Analysis
The indirect axillary or carotid pulse tracing, and the left ventricular echocardiogram including the endocardial border of the septum and the endocardial and epicardial borders of the left ventricular posterior wall, were hand-digitized with a Franklin Quantic 1200 echocardiographic analysis system (Bruce Franklin, Seattle, Washington). This instrument is equipped with a digitizing pad with a sampling rate of 80/cm, giving a maximum net digitizing rate of 800/sec. After data input, the device is programmed to correct the carotid pulse tracing for pulse transmission delay by aligning the dicrotic notch with the first high-frequency component of A2. From the digitized data, the following instantaneous measurements are derived by averaging 3-6 cardiac cycles: 1) pressure during left ventricular ejection determined by linear interpolation with a calibrated carotid pulse tracing as described previously22; 2) left ventricular internal diameter; 3) first derivative of dimension with respect to time, the peak value of this first derivative, and the time from the Q wave to the occurrence of this maximum; 4) left ventricular posterior wall thickness; 5) first derivative of wall thickness with respect to time, the peak value of this first derivative, and the time from the Q wave to the occurrence of this maximum; and 6) the left ventricular wall stress throughout ejection, which was calculated as23 (4) where WS is the wall stress (g/cm2), P is the pressure (mm Hg), D is the dimension, h is the wall thickness (cm), and 1.35 is the conversion factor from mm Hg to g/cm2.
End-diastolic left ventricular dimension and wall thickness were measured at the time of maximum left ventricular dimension, whereas the end-systolic dimension and wall thickness were measured at the time of the first high-frequency component of the second heart sound. Left ventricular ejection time was measured from the simultaneous pulse tracing and adjusted for heart rate by dividing by the square root of the RR interval. The left ventricular percent fractional shortening was calculated as the difference between the dimensions at end diastole and end systole divided by end-diastolic dimension. The rate-adjusted mean velocity of shortening was calculated by dividing fractional shortening by the rate-adjusted ejection time. The left ventricular percent fractional wall thickening was calculated as the difference between the wall thicknesses at end systole and end diastole divided by the end-diastolic wall thickness.
Coronary artery abnormalities were defined in accordance with the criteria outlined by the Japanese Ministry of Health. 24 
Statistical Analysis
We used t tests and analysis of variance to compare groups with respect to unadjusted measured variables. When variables required adjustment for confounders, we used analysis of covari- ance to test for group differences.25 Covariates were selected by prior modeling on normal subjects. The specific covariates for which function variables were adjusted are given in Table 1 .
Using analysis of covariance with a three-level group factor,25 we investigated the effect of treatment with intravenous y-globulin on contractility and function; groups included patients treated with intravenous y-globulin plus aspirin, patients treated with aspirin alone, and normal subjects. To ensure comparability of treatment groups, we analyzed only data on patients from our hospital enrolled in a multicenter, prospective, randomized trial to assess the efficacy of y-globulin (Immuno AG, Vienna, Austria) in reduction of prevalence of coronary artery abnormalities.9 Multiple regression techniques were used to explore the relations between measures of myocardial mechanics and laboratory parameters of systemic inflammation. Statistical analyses were performed with Statistical Analysis Systems (Cary, North Carolina).26
Results

Natural History of Kawasaki Syndrome
Among the 98 children with Kawasaki syndrome, 66 (67%) were male, 16 (16%) had coronary artery abnormalities on at least one echocardiogram, and 57 (58%) received intravenous y-globulin therapy within the first 10 days of the illness. We have summarized in Table 2 the mean ages, body surface areas, and echocardiographic measurements of patients studied within each of five time intervals from onset of the disease as well as those of the 48 normal subjects in whom we obtained twodimensional echocardiographic evaluation of left ventricular function with the same data recording and analytic techniques.
Left ventricular end-diastolic and systolic dimensions, adjusted (with analysis of covariance) for the cubed root of body surface area,27 were significantly higher (both p<0.01) in patients with Kawasaki syndrome within the first 10 days of illness (period 1) than in normal subjects. Both adjusted dimensions tended to be higher in patients during the subsequent four time periods than in normal subjects, but the differences were not significant. Fractional shortening was significantly lower (p<O.O1) in patients during periods 1 and 3 than in normal subjects, but fractional shortening between the two groups was comparable in subsequent periods (later than 3 months after illness onset). Heart rate in patients was higher during period 1 (p<O.O1), which is consistent with the fever and anemia characteristic of the acute phase of the illness. During period 5, patients had a lower mean heart rate than did normal subjects, which may be attributed to their older age. Significant differences were not found between groups in wall thickness, peak or endsystolic wall stress, blood pressure, or fractional wall thickening.
We compared the groups with respect to rateadjusted velocity of shortening (Vcfc), adjusted for end-systolic wall stress,21 as a measure of left ventricular contractility. Contractility was significantly diminished in period 1 (p<0.001) and period To assess the effect of Kawasaki syndrome on the early diastolic function, we examined the peak rates of left ventricular dimension increase and of posterior wall thinning as well as the time to these peak velocities. Using analysis of covariance, we adjusted peak filling rate for fractional shortening and for end-diastolic dimension, factors that have been previously shown to contribute to their variance in normal subjects.28 Peak thinning rate was controlled for fractional wall thinning and for wall thickness difference (end-systolic minus end-diastolic wall thickness). Time to peak filling and peak thinning rates were controlled for the RR interval, based on previous studies.28 We detected no significant differences between patients with Kawasaki syndrome and normal subjects in adjusted peak filling rate, peak thinning rate, time to peak thinning rate, or time to peak filling rate during any period of comparison.
Effect of y-Globulin
We investigated the effect of treatment of acute Kawasaki syndrome with intravenous y-globulin on left ventricular contractility as well as on systolic and early diastolic function. Of 47 children enrolled from our center in a prospective, therapeutic trial, 28 (60%) had been randomized to receive a regimen of intravenous y-globulin (400 mg/kg/day for 4 consecutive days) plus aspirin, and 19 (40%) were randomized to receive aspirin alone. The mean age, body surface area, and measured echocardiographic variables of children treated with y-globulin plus aspirin and of those treated with aspirin alone Values are mean+SD. BSA, body surface area; HR, heart rate; EDD, end-diastolic dimension; ESD, end-systolic dimension; EDH, end-diastolic wall thickness; ESH, end-systolic wall thickness; PFR, peak filling rate; PTR, peak thinning rate; ESWS, end-systolic wall stress; Vcfc, rate-adjusted mean velocity of shortening; FS, fractional shortening; TPTR, time to peak thinning rate; TPFR, time to peak filling rate; FWT, fractional wall thinning. *Significance testing displayed for adjusted measure only (See Table 1 End-systolic Stress (gm/cm2) FIGURE 3. diastolic function. Prior studies did not include children treated with intravenous y-globulin and differed from each other and from the present study in methods of evaluation of myocardial function. These studies have relied on load-dependent indexes of ventricular function such as fractional shortening. We noted a wide range of afterload (endsystolic stress) with rapid changes over time, rendering such indexes incapable of accurately detecting abnormal contractility in these patients. The stressadjusted Vcfc has previously been shown21 to provide a load-independent index of contractility, enabling us to recognize changes in contractility over time and differences between groups.
The optimal methods for normalizing diastolic function parameters remains controversial. In previous studies, we have found such parameters to be dependent on both left ventricular dimensions and on systolic function.28 Adjusting for covariates related to dimension and systolic function, we did not find important differences in early diastolic function between either Kawasaki syndrome patients and control subjects or between patients treated with y-globulin plus aspirin compared with aspirin alone.
In comparing left ventricular contractility among children treated with intravenous y-globulin plus aspirin with that of children treated with aspirin alone, we did not study all patients sequentially in all time periods. Such differential follow-up makes it impossible to exclude selection bias, although the timing of echocardiographic evaluations was determined largely by the patient's ability to cooperate with protocol-specified time windows and was determined by the feasibility of obtaining a stressvelocity analysis related to patient cooperation or sedation. Relatively few children were treated with aspirin alone in period 1 (within 10 days of onset) or with either treatment regimen in period 4 (3-12 months) . For these reasons, it would be desirable for the results reported here on the differential effects of the treatment regimens to be confirmed in a larger study. Such a study probably could not be prospectively performed in North America at the present time because high-dose intravenous yglobulin is almost universally administered for acute Kawasaki syndrome to decrease the prevalence of coronary artery abnormalities.
We conclude that early abnormalities of left ventricular contractility and myocardial performance, as assessed by two-dimensional echocardiography, have generally resolved by 1-3 years after Kawasaki syndrome onset and that recovery is accelerated by administration of high-dose intravenous y-globulin in the acute phase. These data suggest an encouraging long-term outlook for myocardial function in this disease, despite previous reports of persistent late myocardial histologic abnormalities. Assessment of the full impact of Kawasaki syndrome on heart function must await the follow-up of these children into adulthood. .%0 r v.0
